Intracameral triamcinolone acetonide in glaucoma surgery: a prospective randomized controlled trial

To evaluate the efficacy and safety of intracameral triamcinolone acetonide (TA) in glaucoma surgery.

Prospective randomized clinical trial.

Institutional-Wills Eye Hospital.

Patients undergoing trabeculectomy (with or without cataract surgery) or tube shunt surgery.

Patients were randomized to receive intracameral TA or balanced salt solution at the end of surgery. Follow-up time was 6 months.

Intraocular pressure, visual acuity, inflammation measured by slit-lamp examination and laser flare meter, cataract grading, bleb appearance, dry eye scores, use of supplemental medical therapy, surgical success, and rate of complications.

Seventy-seven patients were enrolled in the study, including 37 in the TA group and 40 in the control group. There were no significant differences in success rates between the 2 groups (P=.60). Intraocular pressure and medication use were similar between the groups for each follow-up visit. Dry eye scores were lower in the TA group at month 1 (P=.042), while flare scores were higher in the TA group on day 1 (P=.015) but lower at month 1 (P=.044). The complication rates were higher in the TA group on day 1 (P=.04). All other outcome measures were similar for both groups.

Intracameral TA did not affect the success rates or change the complication rates of glaucoma surgery.